Table 3. Adjusted* odds ratios (ORs) and 95% confidence intervals (CIs) between age and the risk of low Digit Symbol Substitution Test score (<25th percentile of all study subjects, 28 symbols correctly substituted) according to serum concentrations of organochlorine pesticides.
Quintiles of age (years) | |||||||||
---|---|---|---|---|---|---|---|---|---|
Q1 (60–63) | Q2 (64–67) | Q3 (68–72) | Q4 (73–79) | Q5 (80–85) | Ptrend | Pinteraction | |||
(n = 134) | (n = 121) | (n = 124) | (n = 128) | (n = 137) | |||||
P,p’-DDT | T1+T2 | Cases/Subjects | 12/94 | 9/75 | 15/84 | 18/87 | 32/91 | ||
Prevalence (%) | 12.8 | 12 | 17.9 | 20.7 | 35.2 | ||||
Adjusted OR | Reference | 0.6 (0.2–1.6) | 0.8 (0.3–2.0) | 1.6 (0.6-.4.0) | 4.2 (1.7–10.9) | <0.01 | |||
T3 | Cases/Subjects | 14/40 | 16/46 | 17/40 | 15/41 | 20/46 | |||
Prevalence (%) | 35.0 | 34.8 | 42.5 | 36.6 | 43.5 | ||||
Adjusted OR | Reference | 0.8 (0.4–1.6) | 0.8 (0.4–1.7) | 1.2 (0.6–2.4) | 3.1 (0.9–10.5) | 0.25 | 0.37 | ||
P,p’-DDE | T1+T2 | Cases/Subjects | 12/85 | 13/77 | 13/84 | 19/89 | 35/93 | ||
Prevalence (%) | 14.1 | 16.9 | 15.5 | 21.3 | 37.6 | ||||
Adjusted OR | Reference | 1.0 (0.4–2.8) | 0.8 (0.3–2.1) | 1.6 (0.6–4.1) | 4.7 (1.8–12.5) | <0.01 | 0.73 | ||
T3 | Cases/Subjects | 14/49 | 12/44 | 19/40 | 14/39 | 17/44 | |||
Prevalence (%) | 28.6 | 27.3 | 47.5 | 35.9 | 38.6 | ||||
Adjusted OR | Reference | 0.8 (0.3–2.7) | 0.8 (0.3–2.7) | 0.8 (0.3–2.6) | 2.7 (0.8–9.1) | 0.20 | |||
β-hexachlorocyclohexane | T1+T2 | Cases/Subjects | 21/95 | 15/79 | 18/85 | 20/94 | 23/76 | ||
Prevalence (%) | 22.1 | 19.0 | 21.2 | 21.3 | 30.3 | ||||
Adjusted OR | Reference | 0.5 (0.2–1.1) | 0.4 (0.2–1.1) | 0.7 (0.3-.1.6) | 1.6 (0.7–3.9) | 0.30 | <0.01 | ||
T3 | Cases/Subjects | 5/39 | 10/42 | 14/39 | 13/34 | 29/61 | |||
Prevalence (%) | 12.8 | 23.8 | 35.9 | 38.2 | 47.5 | ||||
Adjusted OR | Reference | 2.6 (0.7–10.5) | 2.7 (0.7–10.8) | 5.1 (1.2–21.4) | 11.4 (2.7–48.0) | <0.01 | |||
Trans-nonachlor | T1+T2 | Cases/Subjects | 19/99 | 16/76 | 20/90 | 18/86 | 22/78 | ||
Prevalence (%) | 19.2 | 21.1 | 22.2 | 20.9 | 28.2 | ||||
Adjusted OR | Reference | 0.7 (0.3–1.7) | 0.8 (0.4–1.9) | 1.2 (0.5–2.9) | 2.1 (0.9–5.1) | 0.06 | 0.03 | ||
T3 | Cases/Subjects | 7/35 | 9/45 | 12/34 | 15/42 | 30/59 | |||
Prevalence (%) | 20.0 | 20.0 | 35.3 | 35.7 | 50.8 | ||||
Adjusted OR | Reference | 1.4 (0.4–5.3) | 0.9 (0.2–3.7) | 1.5 (0.4–5.6) | 6.7 (1.7–26.4) | <0.01 | |||
Oxychlordane | T1+T2 | Cases/Subjects | 22/102 | 17/86 | 21/94 | 18/81 | 18/66 | ||
Prevalence (%) | 21.6 | 19.8 | 22.3 | 22.2 | 27.3 | ||||
Adjusted OR | Reference | 0.6 (0.2–1.3) | 0.6 (0.3–1.4) | 1.0 (0.4–2.4) | 1.7 (0.7–4.3) | 0.20 | <0.01 | ||
T3 | Cases/Subjects | 4/32 | 8/35 | 11/30 | 15/47 | 34/71 | |||
Prevalence (%) | 12.5 | 22.9 | 36.7 | 31.9 | 47.9 | ||||
Adjusted OR | Reference | 3.0 (0.6–14.1) | 2.5 (0.6–11.3) | 2.2 (0.5–9.2) | 10.1 (2.4–41.9) | <0.01 | |||
Heptachlor epoxide | T1+T2 | Cases/Subjects | 18/95 | 16/76 | 20/91 | 18/87 | 23/82 | ||
Prevalence (%) | 18.9 | 21.1 | 22.0 | 20.7 | 28.0 | ||||
Adjusted OR | Reference | 0.7 (0.3–1.8) | 0.7 (0.3–1.6) | 0.8 (0.3–1.9) | 1.9 (0.8–4.8) | 0.26 | 0.02 | ||
T3 | Cases/Subjects | 8/39 | 9/45 | 12/33 | 15/41 | 29/55 | |||
Prevalence (%) | 20.5 | 20.0 | 36.4 | 36.6 | 52.7 | ||||
Adjusted OR | Reference | 0.9 (0.3–3.1) | 1.2 (0.3–4.5) | 2.2 (0.7–7.5) | 6.1 (1.7–21.6) | <0.01 |
*Adjusted for age, sex, race-ethnicity, education, poverty income ratio, cigarette smoking, body mass index, physician-diagnosed heart disease, physician-diagnosed hypertension, and physician-diagnosed diabetes